LabCorp

Quanterix Corporation has completed its acquisition of Akoya Biosciences, establishing a scaled leader in early disease detection for neurology, oncology, and immunology markets.

RetinalGenix Technologies has entered into an agreement with LabCorp to support the rollout of its DNA/RNA/GPS Pharmaco-Genetic Mapping platform for early detection of ocular and systemic diseases.

GeneCentric Therapeutics closed an $8 million Series C financing round led by Hatteras Venture Partners to commercialize its GenomicsNext platform, which combines gene expression analysis with DNA variant detection in liquid biopsies.

Predictive Oncology has successfully developed two distinct 3D liver toxicity models exclusively for Labcorp, including human and rat models that represent the liver microenvironment for drug metabolism and toxicity evaluation.

Teal Health's Teal Wand has received FDA approval as the first at-home cervical cancer screening test, offering an alternative to in-clinic pap smears for women aged 25-65 at average risk.

CND Life Sciences has raised $13.5 million in Series A financing, with $8.6 million from its recent Series A3 round, to expand access to its Syn-One Test for detecting neurodegenerative diseases.

Labcorp has entered into an agreement to acquire BioReference Health's oncology and oncology-related clinical testing services for up to $225 million, strengthening its position as a leader in cancer diagnostics.

• The U.S. healthcare contract research organization market is expected to grow from $15.01 billion in 2025 to $29.68 billion by 2034, driven by increasing R&D investments and technological advancements. • Artificial intelligence integration is revolutionizing CRO operations through enhanced clinical trial design, automated data management, and improved patient recruitment, significantly boosting efficiency and productivity. • The preclinical CRO segment is projected to reach $4.66 billion by 2034, with an 8.2% CAGR, as pharmaceutical companies increasingly outsource specialized research services to reduce costs and accelerate drug development.

Labcorp has launched Plasma Detect, a blood-based test using whole-genome sequencing to assess recurrence risk in stage III colon cancer patients by detecting circulating tumor DNA with high sensitivity.

• Ibex Medical Analytics achieves its first FDA 510(k) clearance for Prostate Detect, an AI-powered digital pathology solution that analyzes prostate biopsy slides to identify potential cancer cells. • Clinical validation studies demonstrated exceptional performance with 99.6% positive predictive value and successfully identified 13% of cancer cases initially missed by pathologists. • The AI system showed remarkable accuracy with an AUC of 0.991 for cancer detection and 0.941 for distinguishing between low and high-grade tumors, marking a significant advancement in digital pathology.